Pharmaceutical composition for preventing and treating zearalenone poisoning of pigs

Abstract

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for preventing and treating zearalenone poisoning of pigs, and the pharmaceutical composition comprises the following components in parts by weight: 1-15 parts of morinda officinalis, 1-15 parts of coralhead plant stem with leaf, 1-15 parts of radix bupleuri and 1-15 parts of radix rehmanniae preparata. Research results show that the traditional Chinese medicine composition can relieve the phenomena of red and swollen pudendum and uterine enlargement of the pigs with zearalenone poisoning, accelerate the health recovery of the pigs and reduce economic loss caused by zearalenone poisoning.

Description

Technical Field

[0001] The present application belongs to the field of medical technology, and specifically relates to a pharmaceutical composition for preventing and treating zearalenone poisoning in pigs. Background Art

[0002] Zearalenone (ZEA) is 6-(10-hydroxy-6-oxy-undecenyl)-β-razolactone, a reproductive system toxin with strong teratogenic effects. It can cause a decrease in growth rate, immunosuppression and reproductive disorders in a variety of livestock and poultry, thus posing a serious threat to animal husbandry. Among them, pigs are one of the most common and serious animals damaged by ZEA, because it has a special metabolic mechanism in pigs and is nearly 100 times more sensitive than other animals. It mainly causes reproductive dysfunction in sows, causing sow infertility, estrus disorder, reduced litter size or fetal malformations. At present, the detoxification technology of ZEA is mainly based on adsorption method and biodegradation method. The former still has major problems in adsorption range, practicality, effectiveness and safety. The latter is the development trend of detoxification of ZEA and other mycotoxins, but the research on its degradation mechanism is still not in-depth enough, and the degradation ability of bacteria is unstable and degraded. The foothold of Chinese herbal mycotoxin detoxifiers is to improve the detoxification function of the liver and the kidney, neutralize and antagonize mycotoxins in the body, and achieve the purpose of detoxification by regulating the body state. Using anti-estrogen Chinese medicine to prevent and treat ZEA poisoning in pigs is a more feasible implementation plan. Summary of the invention

[0003] The invention is based on a scientific screening method, and the screened formula is safe and effective, has a good therapeutic effect on poisoning symptoms caused by ZEA toxin, can enhance the detoxification ability of animals themselves, is simple to prepare, low in cost, and is a product with good prospects.

[0004] The specific technical solutions are as follows: A pharmaceutical composition for preventing and treating zearalenone poisoning in pigs comprises the following components in parts by weight: 1-15 parts of Morinda officinalis, 1-15 parts of Acacia sibiricum, 1-15 parts of Bupleurum chinense, and 1-15 parts of Rehmannia glutinosa.

[0005] The pharmaceutical composition of the present invention comprises the following components in parts by weight: 3-10 parts of Morinda officinalis, 3-10 parts of Acacia sibiricum, 2-10 parts of Bupleurum chinense, and 3-10 parts of Rehmannia glutinosa.

[0006] The pharmaceutical composition described in the present invention comprises the following components in parts by weight: 3 parts of Morinda officinalis, 10 parts of Acacia sibiricum, 2 parts of Bupleurum chinense, and 10 parts of Rehmannia glutinosa; or, 3 parts of Morinda officinalis, 3 parts of Acacia sibiricum, 3 parts of Bupleurum chinense, and 3 parts of Rehmannia glutinosa; or, 10 parts of Morinda officinalis, 10 parts of Acacia sibiricum, 5 parts of Bupleurum chinense, and 5 parts of Rehmannia glutinosa; or, 5 parts of Morinda officinalis, 5 parts of Acacia sibiricum, 10 parts of Bupleurum chinense, and 10 parts of Rehmannia glutinosa; or, 5 parts of Morinda officinalis, 10 parts of Acacia sibiricum, 10 parts of Bupleurum chinense, and 5 parts of Rehmannia glutinosa.

[0007] The invention provides a method for preparing a pharmaceutical composition, which comprises crushing raw materials of traditional Chinese medicine by a crusher and then premixing them uniformly.

[0008] The pharmaceutical composition of the present invention is used for preventing and treating zearalenone poisoning in pigs.

[0009] Specifically, the present invention provides the following embodiments: Example 1: Morinda officinalis 3g, Acacia scabra 10g, Bupleurum 2g, Rehmannia glutinosa 10g; each component was weighed and crushed, and passed through a 40-mesh sieve.

[0010] Example 2: Morinda officinalis 3g, Acacia scabra 3g, Bupleurum 3g, Rehmannia glutinosa 3g; each component was weighed and crushed, and passed through a 40-mesh sieve.

[0011] Example 3: Morinda officinalis 10g, Acacia scabra 10g, Bupleurum 5g, Rehmannia glutinosa 5g; each component was weighed and crushed, and passed through a 40-mesh sieve.

[0012] Example 4: Morinda officinalis 5g, Acacia scabra 5g, Bupleurum 10g, Rehmannia glutinosa 10g; each component was weighed and crushed, and passed through a 40-mesh sieve.

[0013] Example 5: Morinda officinalis 5g, Acacia scabra 10g, Bupleurum 10g, Rehmannia glutinosa 5g; each component was weighed and crushed, and passed through a 40-mesh sieve.

[0014] Compared with the prior art, the present invention achieves the following beneficial technical effects: The research results of the present invention show that the redness and swelling of the vulva and uterine enlargement of pigs poisoned by zearalenone can be alleviated, the health recovery of pigs can be accelerated, and the economic losses caused by zearalenone toxin poisoning can be reduced. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 Example 1: The appearance of the pig vulva and secretions at the beginning of the test; Figure 2 Example 1: The appearance of the pig vulva and secretions at the beginning of the test; Figure 3 Example 1: Performance of the pig vulva and secretions during the mid-term test; Figure 4 Example 1 Group test ended the performance of pig vulva and secretions; Figure 5The appearance of the pig vulva and secretions at the beginning of the test of the mold remover group; Figure 6 The appearance of the pig vulva and secretions at the end of the test of the mold remover group; Figure 7 The appearance of the pig vulva and secretions at the end of the blank control group test; Figure 8 Vulvar symptoms of piglets born by sows in Example 1; Fig. 9 Vulvar symptoms of piglets born by sows in the mold removal agent group; Fig.10 Vulvar symptoms of piglets born by sows in the blank control group. DETAILED DESCRIPTION

[0015] The present invention can be better understood according to the following examples. However, it is easy for those skilled in the art to understand that the contents described in the examples are only used to illustrate the present invention, and should not and will not limit the present invention described in detail in the claims.

[0016] Test Example 1: Screening test of components in drug compositions Testing indicators: body weight, uterine index and estrogen content (E2) are used as indicators for testing; Experimental method: The drug was challenged by oral gavage at a dose of 1.00 mg / kg·bw for 10 consecutive days, and the drug was administered after the model was successfully established.

[0017] Experimental animals: Kunming mice, 20-22 g.

[0018] Test results: The specific values ​​are shown in the following table. In order to more directly and obviously judge the effect of the drug, the year-on-year index is used to normalize the data. The year-on-year index = prescription group / model group.

[0019] Table 1 Prescription drug composition

[0020] Table 2 Grouping and drug administration

[0021] The pharmacological effect was calculated and analyzed using the difference between the group and the model group as an indicator. The specific results are shown in Table 3: Table 3 Optimization screening test results

[0022] Result analysis: This time, the orthogonal t value method was used to design the formula according to the research basis of modern pharmacology. The test results showed that the two herbs with significant anti-estrogen effects (main drugs) were Morinda officinalis and Acacia scabra, while Bupleurum chinense and Rehmannia glutinosa had no significant effects (auxiliary drugs). Epimedium, Licorice, Angelica sinensis and Pueraria root had adverse effects; Chuanxiong, Paojiang and Safflower had no significant effects.

[0023] The optimal combination of prescriptions is: Morinda officinalis, Acacia sylvestris, Bupleurum chinense, and Rehmannia glutinosa. This combination of four herbs can achieve the highest anti-estrogen effect.

[0024] Test Example 2: Clinical Effect of the Pharmaceutical Composition Materials and Methods Mold removers and test animals Example 1 is homemade, and the control uses a pig farm mold removal agent (the main component is montmorillonite); the farrowing sows are provided by a pig farm in Luoyang City, and the test pigs all have a history of eating moldy feed. After quantitative detection, it was found that they contained ZEA toxin, and the clinical manifestation was swollen labia.

[0025] Clinical efficacy verification test 9 sows with similar parity, similar weight and ZEA poisoning were randomly divided into 3 groups, 3 in each group, and isolated and raised, respectively, as Example 1, a mold removal agent control group and a blank control group. The specific operation is shown in Table 4. All were continuously administered for 17 days, and the drugs should be fully stirred and mixed when added. After administration, the vulva state of the test pigs (including redness, swelling, and secretions) was carefully observed every day, and the average daily feed intake, farrowing rate, abortion rate, number of surviving piglets per litter, litter weight, feed-to-meat ratio and health status were recorded.

[0026] Table 4 Clinical effect verification of traditional Chinese medicine detoxification agents

[0027] Results and Analysis Vulva status observation The results are shown in Table 5. It can be seen from Table 5 that in the Example 1 group, the pig vulva and secretions showed clinical disease at the beginning of the experiment ( Figure 1 )( Figure 2 ), the redness and swelling of the vulva were alleviated after the 8th and 9th days of feeding ( Figure 3 ), after 17 days of feeding, the redness, swelling and discharge of the vulva disappeared ( Figure 4 ); It is suggested that Example 1 has a more obvious effect on ZEA poisoning.

[0028] In the mold removal agent group, the vulva of each pig was severely red and swollen at the beginning of the experiment ( Figure 5 ); symptoms were alleviated by the end of the trial ( Figure 6 ), but it was relatively serious compared with the group in Example 1, indicating that the detoxification agent has a detoxification effect on ZEA poisoning pigs, but the effect is not as obvious as that in Example 1.

[0029] In the blank control group, the redness and swelling of the pig's vulva did not change significantly from the beginning to the end of the experiment, and the clinical symptoms were only slightly alleviated ( Figure 7 ). Without the use of mold removal products, the self-healing speed of pigs after poisoning is slower.

[0030] Table 5 Vulva status record

[0031] Note 1: (1) None: no vulvar symptoms, scored as “0 points”; (2) Mild: There are very mild symptoms on the vulva that are not easily noticed and do not affect daily activities, food intake, or weight gain, and it is recorded as "1 point"; (3) Moderate: Mild symptoms can be observed on the vulva, but there is no significant interference with normal daily activities and production performance, which is scored as "2 points"; (4) Slightly more: Obvious symptoms can be observed on the vulva, which significantly interfere with daily activities and production performance, and is scored as "3 points"; (5) Severe: severe vulvar symptoms that interfere greatly with daily activities and production performance, affecting production performance, scored as “4 points”; Determination of production performance related indicators The results are shown in Table 6. It can be seen from Table 6 that the farrowing rates of the three test groups were all 100%, and no abortion occurred. The litter survival rates of all pigs in the Example 1 group and the mold removal agent group were 100%, and the litter survival rates of the control group were 90.9%, 100% and 83.3% respectively; the average litter weight was the highest in the Example 1 group, and the lowest in the control group.

[0032] The pigs in the Example 1 group gave birth on the 14th, 16th and 31st days of feeding, and the piglets were normal in vulva ( Figure 8 The pigs in the mold removal agent group gave birth on the 13th, 17th and 31st days of feeding, and the piglets had slight swelling of the vulva ( Fig. 9 ); In the blank control group, pigs C1, C2 and C3 gave birth on the 13th, 17th and 31st days of feeding, respectively, and the piglets had swollen vulva ( Fig.10 ).

[0033] Table 6 Determination of production performance related indicators

[0034] Conclusion and discussion The screening of formulas is crucial for preventing ZEA poisoning in pigs. The results of clinical verification tests on ZEA-poisoned sows using Example 1 prepared from a traditional Chinese medicine compound show that Example 1 has a significant detoxifying effect on ZEA. Comprehensive evaluation results show that Example 1 has a more significant effect than commonly used de-mold agents on the market, and the present invention has outstanding effect advantages.

Claims

1. A pharmaceutical composition for preventing and treating zearalenone poisoning in pigs, characterized in that: The invention comprises the following components in parts by weight: 1-15 parts of Morinda officinalis, 1-15 parts of Acacia scabra, 1-15 parts of Bupleurum chinense and 1-15 parts of Rehmannia glutinosa.

2. The pharmaceutical composition according to claim 1, characterized in that The invention comprises the following components in parts by weight: 3-10 parts of Morinda officinalis, 3-10 parts of Acacia scabra, 2-10 parts of Bupleurum chinense and 3-10 parts of Rehmannia glutinosa.

3. The pharmaceutical composition according to claim 2, characterized in that Contains the following components in parts by weight, 3 parts of Morinda officinalis, 10 parts of Acacia chinensis, 2 parts of Bupleurum chinense, and 10 parts of Rehmannia glutinosa; Or, 3 parts of Morinda officinalis, 3 parts of Acacia scabra, 3 parts of Bupleurum chinense, and 3 parts of Rehmannia glutinosa; Or, Morinda officinalis 10 parts, Acacia sylvestris 10 parts, Bupleurum 5 parts, Rehmannia glutinosa 5 parts; Or, Morinda officinalis 5 parts, Acacia sinensis 5 parts, Bupleurum 10 parts, Rehmannia glutinosa 10 parts; Alternatively, 5 parts of Morinda officinalis, 10 parts of Acacia sylvestris, 10 parts of Bupleurum chinense, and 5 parts of Rehmannia glutinosa.

4. The method for preparing the pharmaceutical composition according to any one of claims 1 to 3, characterized in that: The raw materials of Chinese medicine can be crushed with a pulverizer and premixed evenly.

5. Use of the pharmaceutical composition according to any one of claims 1 to 3 for preventing and treating zearalenone poisoning in pigs.

Images